Literature DB >> 33692940

MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.

Yan Zhu1,2, Jin-Min Sun1,2,3, Zi-Chen Sun1, Feng-Jiao Chen1, Yong-Ping Wu3, Xiao-Yu Hou1,2.   

Abstract

Mixed lineage kinase 3 (MLK3) has been implicated in human melanoma and breast cancers. However, the clinical significance of MLK3 in human gliomas and the underlying cellular and molecular mechanisms remain unclear. We found that MLK3 proteins were highly expressed in high-grade human glioma specimens and especially prevalent in primary and recurrent glioblastoma multiforme (GBM). High levels of MLK3 mRNA were correlated with poor prognosis in patients with isocitrate dehydrogenase (IDH)-wild-type (wt) gliomas. Furthermore, genetic ablation of MLK3 significantly suppressed the migration and invasion abilities of GBM cells and disrupted actin cytoskeleton organization. Importantly, MLK3 directly bound to epidermal growth factor receptor kinase substrate 8 (EPS8) and regulated the cellular location of EPS8, which is essential for actin cytoskeleton rearrangement. Overall, these findings provide evidence that MLK3 upregulation predicts progression and poor prognosis in human IDH-wt gliomas and suggest that MLK3 promotes the migration and invasion of GBM cells by remodeling the actin cytoskeleton via MLK3-EPS8 signaling.
Copyright © 2021 Zhu, Sun, Sun, Chen, Wu and Hou.

Entities:  

Keywords:  actin cytoskeleton remodeling; epidermal growth factor receptor kinase substrate 8 (EPS8); glioblastoma prognosis; glioma progression; isocitrate dehydrogenase (IDH); mixed lineage kinase 3 (MLK3); primary and recurrent glioblastoma multiforme (GBM)

Year:  2021        PMID: 33692940      PMCID: PMC7937953          DOI: 10.3389/fonc.2020.600762

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  1 in total

1.  Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.

Authors:  Hao Li; Di Wang; Bolong Yi; Heng Cai; Zhuo Xi; Xin Lou; Zhen Li
Journal:  Biomed Res Int       Date:  2021-08-05       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.